SCND · Scientific Industries Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.23M | - | $1.40M | $2.33M | $2.41M | - | $2.77M | $2.65M | $2.48M | - |
| Cost of Revenue | $757.2K | - | $765.4K | $1.31M | $1.39M | - | $1.41M | $1.35M | $1.44M | - |
| Gross Profit | $469.9K | - | $638.6K | $1.02M | $1.02M | - | $1.36M | $1.29M | $1.04M | - |
| R&D | $703.7K | - | $621.4K | $677.2K | $652.0K | - | $683.2K | $666.0K | $710.7K | - |
| SG&A | $746.9K | - | $803.6K | $975.8K | $1.25M | - | $1.02M | $1.06M | $1.52M | - |
| Total Operating Expenses | $2.14M | - | $2.16M | $2.57M | $2.83M | - | $2.62M | $2.63M | $3.13M | - |
| D&A | $55.3K | - | - | - | $166.7K | - | - | - | $188.1K | - |
| Operating Income | ($1.67M) | - | ($1.52M) | ($1.55M) | ($1.81M) | - | ($1.26M) | ($1.34M) | ($2.09M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | $0 | - | $0 | $0 | $0 | - |
| Net Income | ($1.59M) | - | $3.99M | ($1.52M) | ($1.78M) | - | ($1.18M) | ($1.28M) | ($2.05M) | - |
| EPS - Basic | - | - | - | - | - | - | - | - | - | - |
| EPS - Diluted | ($0.13) | - | $0.34 | ($0.12) | $0.20 | - | ($0.31) | - | - | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $797.8K | $955.0K | $1.16M | $891.4K | $470.1K | $587.9K | $563.5K | $560.5K | $351.7K | $796.1K |
| Accounts Receivable | $535.3K | $865.8K | $677.6K | $966.0K | $1.21M | $1.20M | $1.36M | $1.21M | $1.14M | $1.16M |
| Inventory | $1.57M | $1.40M | $2.04M | $4.39M | $4.35M | $4.09M | $5.39M | $5.40M | $4.87M | $4.88M |
| Accounts Payable | $405.5K | $449.1K | $515.1K | $651.4K | $973.4K | $586.1K | $615.3K | $712.6K | $767.4K | $711.7K |
| Current Assets | $8.99M | $10.39M | $11.89M | $7.21M | $7.39M | $8.29M | $9.65M | $10.39M | $11.40M | $12.34M |
| Total Assets | $11.10M | $12.61M | $14.56M | $10.23M | $10.57M | $11.56M | $13.31M | $14.28M | $15.55M | $16.73M |
| Current Liabilities | $1.45M | $1.35M | $1.55M | $1.70M | $2.13M | $1.75M | $1.61M | $1.77M | $2.05M | $1.84M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $1.99M | $1.94M | $2.10M | $2.23M | $2.80M | $2.44M | $2.37M | $2.59M | $2.93M | $2.85M |
| Stockholders' Equity | $9.12M | $10.66M | $12.46M | $7.92M | $7.77M | $9.12M | $10.93M | $11.68M | $12.62M | $13.89M |
| Retained Earnings | ($36.74M) | ($35.15M) | ($33.24M) | ($37.23M) | ($35.71M) | ($33.93M) | ($32.00M) | ($30.82M) | ($29.54M) | ($27.49M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($993.5K) | - | - | - | ($1.33M) | - | - | - | ($1.57M) | - |
| Investing Cash Flow | $813.9K | - | - | - | $1.20M | - | - | - | $480.6K | - |
| Financing Cash Flow | $0 | - | - | - | $0 | - | - | - | $645.7K | - |
| CapEx | $6.2K | - | - | - | $26.3K | - | - | - | $47.5K | - |
| Free Cash Flow | ($999.7K) | - | - | - | ($1.36M) | - | - | - | ($1.61M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 38.3% | - | 45.5% | 43.8% | 42.2% | - | 49.2% | 48.8% | 41.9% | - |
| Operating margin | -135.9% | - | -108.4% | -66.3% | -75.3% | - | -45.5% | -50.5% | -84.1% | - |
| EBITDA margin | -131.4% | - | - | - | -68.3% | - | - | - | -76.6% | - |
| Net margin | -129.5% | - | 284.5% | -65.4% | -73.9% | - | -42.6% | -48.5% | -82.6% | - |
| Free cash flow margin | -81.5% | - | - | - | -56.4% | - | - | - | -64.9% | - |
| FCF / Net income | 0.63 | - | - | - | 0.76 | - | - | - | 0.79 | - |
| R&D / Revenue | 57.3% | - | 44.3% | 29.1% | 27.1% | - | 24.7% | 25.2% | 28.6% | - |
| SG&A / Revenue | 60.9% | - | 57.2% | 41.9% | 52.0% | - | 36.8% | 40.1% | 61.3% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -14.3% | - | 27.4% | -14.9% | -16.8% | - | -8.9% | -9.0% | -13.2% | - |
| Return on equity | -17.4% | - | 32.1% | -19.2% | -22.9% | - | -10.8% | -11.0% | -16.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 6.22 | 7.70 | 7.65 | 4.25 | 3.47 | 4.74 | 5.99 | 5.85 | 5.56 | 6.72 |
| Quick ratio | 5.14 | 6.66 | 6.34 | 1.66 | 1.42 | 2.41 | 2.65 | 2.81 | 3.19 | 4.06 |
| Cash ratio | 0.55 | 0.71 | 0.75 | 0.53 | 0.22 | 0.34 | 0.35 | 0.32 | 0.17 | 0.43 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.22 | 1.18 | 1.17 | 1.29 | 1.36 | 1.27 | 1.22 | 1.22 | 1.23 | 1.20 |
| Liabilities / Assets | 0.18 | 0.15 | 0.14 | 0.22 | 0.27 | 0.21 | 0.18 | 0.18 | 0.19 | 0.17 |
| Efficiency | ||||||||||
| Asset turnover | 0.11 | - | 0.10 | 0.23 | 0.23 | - | 0.21 | 0.19 | 0.16 | - |
| Inventory turnover | 0.48 | - | 0.37 | 0.30 | 0.32 | - | 0.26 | 0.25 | 0.30 | - |
| Days sales outstanding | 159d | - | 176d | 151d | 183d | - | 179d | 168d | 168d | - |
| Days inventory outstanding | 755d | - | 975d | 1224d | 1143d | - | 1398d | 1454d | 1232d | - |
| Days payable outstanding | 195d | - | 246d | 181d | 256d | - | 160d | 192d | 194d | - |
| Cash conversion cycle | 719d | - | 905d | 1194d | 1071d | - | 1417d | 1429d | 1206d | - |
| Valuation | ||||||||||
| P / E | - | - | 2.1x | - | 4.7x | - | - | - | - | - |
| P / B | 1.0x | - | 0.7x | - | 1.3x | - | 1.2x | 1.2x | 1.7x | - |
| P / S | 7.1x | - | 5.8x | - | 4.1x | - | 4.9x | 5.4x | 8.4x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -49.0% | - | -49.3% | -12.0% | -3.1% | - | 7.1% | -11.2% | -11.5% | - |
| Revenue CAGR (3y) | -24.1% | - | -21.2% | -7.1% | -3.4% | - | 3.3% | -0.9% | -4.5% | - |
| Revenue CAGR (5y) | -15.5% | - | -10.0% | 0.5% | 3.7% | - | -1.9% | 6.9% | 14.2% | - |
| Gross profit growth (YoY) | -53.8% | - | -53.2% | -21.1% | -2.3% | - | 15.4% | 1.9% | -22.2% | - |
| Operating income growth (YoY) | 7.9% | - | -21.0% | -15.7% | 13.3% | - | 43.4% | 40.0% | 15.3% | - |
| Net income growth (YoY) | 10.6% | - | - | -18.6% | 13.3% | - | 46.4% | 87.2% | 13.5% | - |
| EPS growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 26.4% | - | - | - | 15.8% | - | - | - | 2.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 17.3% | 16.9% | 14.0% | -32.2% | -38.4% | -34.3% | 10.7% | 3.1% | -3.4% | - |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$10.11M totalConsolidated Entity$5.05M · 50.0%
Benchtop Laboratory Equipment$3.75M · 37.1%
Bioprocessing Systems$1.30M · 12.9%
Product / service
$115.1K totalSubscriptions$115.1K · 100.0%
Peer comparison
Same SIC group: Laboratory Analytical Instruments
Comparing SCIENTIFIC INDUSTRIES INC against the 5 most active filers in the same SIC group.
Dividends
$0.00/share trailing 12 months
| Ex-date | Per share |
|---|---|
| Nov 27, 2018 | $0.0500 |
| Nov 21, 2016 | $0.0300 |
| Oct 9, 2013 | $0.0800 |
| Sep 27, 2012 | $0.3000 |
| Sep 22, 2011 | $0.0500 |
| Oct 14, 2010 | $0.0900 |
| Oct 21, 2009 | $0.0600 |
| Oct 23, 2008 | $0.0800 |
| Oct 25, 2007 | $0.0700 |
| Oct 26, 2006 | $0.0700 |
| Oct 25, 2005 | $0.0900 |
| Oct 18, 2004 | $0.0700 |
| Mar 2, 2004 | $0.0500 |